Investigation of Active Components of Meconopsis integrifolia (Maxim.) Franch in Mitigating Non-Alcoholic Fatty Liver Disease
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms26010050 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Qiqin Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for High Altitude Medicine, Key Laboratory of the Ministry of High Altitude Medicine, Key Laboratory of Applied Fundamentals of High …. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Plant Extracts. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Research Fund of Qinghai University, Basic Research Programme of Qinghai Province.
Abstract (Originalsprache)
Nonalcoholic fatty liver disease (NAFLD) has rapidly emerged as the most prevalent chronic liver disease globally, representing a significant and escalating public health challenge. Meconopsis integrifolia (Maxim.) Franch, a traditional Tibetan medicinal herb used for treating hepatitis, remains largely unexplored regarding its therapeutic potential and active components in combating NAFLD. This study first evaluated the in vitro lipid accumulation inhibitory activity of different extraction fractions of M. integrifolia using a HepG2 cell steatosis model. The ethyl acetate fraction was found to significantly reduce triglyceride (TG) and low-density lipoprotein (LDL) levels, inhibit lipid droplet deposition in HepG2 cells, and promote lipid metabolism balance through modulation of the AMPK/SREPB-1c/PPAR-α signaling pathway. Further analysis utilizing chromatographic techniques and nuclear magnetic resonance spectroscopy (NMR) led to the isolation of 13 compounds from the active ethyl acetate fraction. Notably, compounds 6, 9, 10, 11, 12, and 13 were identified for the first time from this Tibetan herb. In vitro activity assays and molecular docking analyses further confirmed that the compounds Luteolin (1), Quercetin 3-O-[2‴, 6‴-O-diacetyl-β-d-glucopyranosyl-(1→6)-β-d-glucopyranoside] (6), and Quercetin 3-O-[2‴-O-acetyl-β-d-glucopyranosyl-(1→6)-β-d-glucopyranoside] (8) are potential key components responsible for the NAFLD-ameliorating effects of M. integrifolia. This study highlights the therapeutic potential of M. integrifolia in treating NAFLD and provides a foundation for its further development and application, underscoring its significance in the advanced utilization of traditional Tibetan medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for High Altitude Medicine, Key Laboratory of the Ministry of High Altitude Medicine, Key Laboratory of Applied Fundamentals of High Altitude Medicine (Qinghai-Utah Joint Key Laboratory of Plateau Medici…
- College of Chemical Engineering, Qinghai University, Xining 810016, China.
- College of Eco-Environmental Engineering, Qinghai University, Xining 810016, China.
ORCID-Profile: Dejun Zhang
Förderung
- Youth Research Fund of Qinghai University
- Basic Research Programme of Qinghai Province
Zitieren
APA
Lu, Q., La, M., Wang, Z., Huang, J., Zhu, J., & Zhang, D. (2024). Investigation of Active Components of Meconopsis integrifolia (Maxim.) Franch in Mitigating Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26010050
Vancouver
Lu Q, La M, Wang Z, Huang J, Zhu J, Zhang D. Investigation of Active Components of Meconopsis integrifolia (Maxim.) Franch in Mitigating Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms26010050
BibTeX
@article{Lu2024,
author = {Lu, Qiqin and La, Majia and Wang, Ziyang and Huang, Jiaomei and Zhu, Jiahui and Zhang, Dejun},
title = {Investigation of Active Components of Meconopsis integrifolia (Maxim.) Franch in Mitigating Non-Alcoholic Fatty Liver Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms26010050}
}
EUVIMED